Astellas Pharma Europe Ltd.

STAINES, England, November 4, 2011 - Astellas Pharma Europe Ltd., is pleased to announce it is the proud recipient of the Scrip Award for Licensing Deal of theYear at the 7thAnnual Scrip Awards ceremony, which took place last night at London's Grosvenor House Hotel.

STAINES, England, May 20, 2011 - Astellas Pharma Europe Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorisation for VIBATIV (telavancin hydrochloride) for the treatment for adults with nosocomial (hospital-acquired) pneumonia, including ventilator associated pneumonia known or suspected to be caused by MRSA (methicillin resistant Staphylococcus aureus).

STAINES, England, May 3, 2011 - Astellas Pharma Europe Ltd today announced that the results of the 6-month OSAKA study demonstrate that tacrolimus prolonged release (QD; ADVAGRAF(R), Graceptor(R) in Japan)-based therapy is non-inferior to the same daily dose of tacrolimus immediate release (BID; PROGRAF(TM))-based therapy (0.2mg/kg/day) for efficacy in renal transplantation.

LONDON, April 11, 2011 - New survey data released today demonstrate that childhood eczema can have a detrimental effect on quality of life not only for the children who live with the disease, but also for their families.[1a] The survey, which was carried out in eight countries across Europe, examines the impact of eczema on European children through the eyes of the parents who care for them.

STAINES, England, April 11, 2011 - Astellas Pharma Europe Ltd.